Iovance Biotherapeutics (Mfg)

Philadelphia, PA
Find alternatives to Iovance Biotherapeutics (Mfg) for Cell Therapy →
In-house manufacturer
31 confirmed programs · 12 sponsors · Last scored 2026-10-29
65.9
Signal Score
○ FDA Inspections ✓ Clinical Trials (31) ✓ SEC Filings (20) ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Iovance Biotherapeutics (Mfg)

Signal Score
65.9/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
Philadelphia, PA
Modalities
Cell Therapy
Active Programs
31 confirmed from ClinicalTrials.gov across 12 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Iovance Biotherapeutics (Mfg)

CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 74.5
31 active programs across 12 sponsors
Modalities: Cell Therapy
20 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
31 active programs across 12 sponsors · Modalities: Cell Therapy · 20 programs in advanced phases (Phase 2/3)
Programs 31
Sponsors12
ModalitiesCell Therapy
31 active programs across 12 sponsors
Modalities: Cell Therapy
20 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07700121 PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel... EARLY_PHASE1 Not Yet Recruiting
NCT07741877 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in... PHASE2 Not Yet Recruiting
NCT07192900 Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease PHASE1 Recruiting
NCT07288073 TIL Therapy in cSCC and MCC PHASE2 Recruiting
NCT07288203 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in... PHASE2 Active Not Recruiting
NCT05639972 E7 T-cell Receptor (TCR) -T Cell Induction Therapy for... PHASE1/PHASE2 Recruiting
NCT06940739 A Study to Investigate the Safety and Efficacy of IOV-3001 in... PHASE1/PHASE2 Recruiting
NCT06481592 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in... PHASE2 Recruiting
NCT06151847 Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide... PHASE2 Completed
NCT05727904 Study to Investigate Lifileucel Regimen Plus Pembrolizumab... PHASE3 Recruiting
View all 31 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 68.0
Parent company: Iovance Biotherapeutics
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
20 SEC filings with industry mentions on record (shown, not scored)
SEC Filings20 with industry mentions (not scored)
Parent company: Iovance Biotherapeutics
Financial assessment: 68.0/100
Capacity 53.0
1 manufacturing site: Philadelphia, PA
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: Philadelphia, PA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Philadelphia, PA
Modalities: Cell Therapy
Capacity assessment: 53.0/100

Clinical Activity 31 studies

NCT07700121 PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma EARLY_PHASE1 Not Yet Recruiting NCT07741877 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With... PHASE2 Not Yet Recruiting NCT07192900 Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease PHASE1 Recruiting NCT07288073 TIL Therapy in cSCC and MCC PHASE2 Recruiting NCT07288203 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With... PHASE2 Active Not Recruiting NCT05639972 E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally... PHASE1/PHASE2 Recruiting NCT06940739 A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With... PHASE1/PHASE2 Recruiting NCT06481592 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With... PHASE2 Recruiting NCT06151847 Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion... PHASE2 Completed NCT05727904 Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With... PHASE3 Recruiting NCT05686226 E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers PHASE2 Recruiting NCT05607095 A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma,... PHASE1 Recruiting NCT05483491 KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer PHASE1 Recruiting NCT05361174 A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in... PHASE1/PHASE2 Recruiting NCT05176470 Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for... PHASE1 Active Not Recruiting NCT04614103 Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer PHASE2 Recruiting NCT04155710 Study of Autologous Peripheral Blood Lymphocytes in the Treatment of... PHASE1 Completed NCT04111510 Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated... PHASE2 Completed NCT04052334 Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent... PHASE1 Completed NCT03935347 Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in... PHASE2 Withdrawn
+ 11 more studies
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026

Hiring Activity 9 open roles Beta

From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
9
open roles
6
in manufacturing, quality, PD/MSAT, engineering or regulatory (67%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 0 new postings, 29 taken down.
By function
Manufacturing & operations 3
Quality (QA / QC) 1
Process development & MSAT 1
Engineering & facilities 1
Commercial, BD & client projects 1
Other (finance, HR, IT, other) 2
By site
Philadelphia, PA profile site
3 mfg/ops · 1 QA/QC · 1 eng. · 1 other
6
iCTC
· 1 PD/MSAT · 1 other
2
Tampa, FL/ ICTC Philadelphia, PA / Hybrid
· 1 other
1
Latest postings
Vice President, Research Other (finance, HR, IT, other) · Tampa, FL/ ICTC Philadelphia, PA / Hybrid · posted Nov 18, 2026
AI Strategist, Technical Operations & Finance Process development & MSAT · iCTC · posted Nov 16, 2026
Logistics & Planning Associate II Manufacturing & operations · Philadelphia · posted Nov 2, 2026
Manager, Quality Assurance Operations Quality (QA / QC) · Philadelphia, Pennsylvania · posted Oct 29, 2026
Aseptic Manufacturing Technician I - Night Shift B [Contract to Hire] Manufacturing & operations · Philadelphia, PA · posted Jun 23, 2026
Aseptic Manufacturing Technician I - Day Shift B [Contract to Hire] Manufacturing & operations · Philadelphia, PA · posted Jul 31, 2026
Instrumentation & Equipment Specialist II (3rd Shift Sunday - Wednesday, 10:00pm - 8:30am) Engineering & facilities · Philadelphia, Pennsylvania · posted Sep 24, 2026
Senior Project Manager Commercial, BD & client projects · Philadelphia, PA · posted Aug 27, 2026
Senior Manager, Cost Accounting Other (finance, HR, IT, other) · iCTC · posted Aug 20, 2026
Coverage: read from the parent company's careers board and kept only postings at this business's sites (Iovance Cell Therapy Center (iCTC), Philadelphia only; the rest of the board is the biotech's R&D, commercial and remote roles). Roles outside those sites are left out, and some of this unit's roles may be missed. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: job-boards.greenhouse.io · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Financial Intelligence

8-K 2026-10-05 0 keyword mentions
8-K 2026-09-29 0 keyword mentions
"Item 8.01 Other Events: On September 29, 2026, Iovance Biotherapeutics, Inc. issued a press"
10-Q 2026-08-06 60 keyword mentions
"The Company was founded to build upon the promise of TIL cell therapy initially developed at academic research centers, including the National Cancer Institute (“NCI”)."
"The Company’s multi-center trials, scalable manufacturing, regulatory approvals, and commercial infrastructure have transformed TIL cell therapy from a research product available to only a small number of patients into a commercially viable treatment that is accessible for thousands of cancer patients."
"Amtagvi ® is the first one-time, individualized T cell therapy for a solid tumor cancer and for the treatment of adult patients with previously treated advanced melanoma, defined as unresectable or metastatic melanoma, approved for use in the U.S., Canada, and Australia."
8-K 2026-08-06 0 keyword mentions
8-K 2026-08-06 0 keyword mentions
"Item 2.02 ,: including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities"
8-K 2026-07-02 0 keyword mentions
10-Q 2026-05-07 61 keyword mentions
"The Company was founded to build upon the promise of TIL cell therapy initially developed at academic research centers, including the National Cancer Institute (“NCI”)."
"The Company’s multi-center trials, scalable manufacturing, regulatory approvals, and commercial infrastructure have transformed TIL cell therapy from a research product available to only a small number of patients, into a commercially viable treatment that is accessible for thousands of cancer patients."
"Amtagvi ® is the first one-time, individualized T cell therapy for a solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanoma, approved for use in the U.S."
8-K 2026-03-20 0 keyword mentions
10-K 2026-02-24 100 keyword mentions
"​ Iovance was founded to build upon the promise of TIL cell therapy initially developed at academic research centers, including the National Cancer Institute, or the NCI."
"Our multi-center trials, scalable manufacturing, regulatory approvals and commercial infrastructure have transformed TIL cell therapy from a research product available to only a small number of patients, into a commercially viable treatment that is accessible for thousands of cancer patients."
"​ Amtagvi ® is the first one-time, individualized T cell therapy for a solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanoma."
8-K 2026-02-24 0 keyword mentions
8-K 2026-01-09 0 keyword mentions
10-Q 2025-11-06 94 keyword mentions
"launch of Amtagvi ® (lifileucel), the first product within its autologous TIL cell therapy platform, while also marketing Proleukin ® (aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi ® treatment regimen and in other applications."
"Amtagvi ® is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
8-K 2025-11-06 0 keyword mentions
8-K 2025-08-29 0 keyword mentions
10-Q 2025-08-07 95 keyword mentions
"launch of Amtagvi ® (lifileucel), the first product within its autologous TIL cell therapy platform, while also marketing Proleukin ® (aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi ® treatment regimen and in other applications."
"Amtagvi ® is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
10-Q 2025-05-08 102 keyword mentions
"launch of Amtagvi ® (lifileucel), the first product within its autologous TIL cell therapy platform, while also marketing Proleukin ® (aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi ® treatment regimen and in other applications."
"Amtagvi ® is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
10-K 2025-02-27 180 keyword mentions
"launch of Amtagvi ® (lifileucel), the first product within our autologous TIL cell therapy platform, while also marketing Proleukin ® (aldesleukin), an interleukin-2, or IL-2, product used in the Amtagvi ® treatment regimen and in other applications."
"Amtagvi ® is the first and the only one-time, individualized T cell therapy to receive FDA approval for a solid tumor cancer."
"Iovance was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute, or the NCI."
10-Q 2024-11-07 94 keyword mentions
"launch of Amtagvi™ (lifileucel), the first product within its autologous TIL cell therapy platform, while also marketing Proleukin ® (aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi™ treatment regimen."
"Amtagvi™ is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
10-Q 2024-08-08 93 keyword mentions
"launch of Amtagvi™ (lifileucel), the first product within its autologous TIL cell therapy platform, and Proleukin ® (aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi™ treatment regimen."
"Amtagvi™ is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
10-Q 2024-05-09 94 keyword mentions
"launch of Amtagvi™ (lifileucel), the first product within its autologous TIL cell therapy platform, and Proleukin ® (aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi™ treatment regimen."
"Amtagvi™ is the first and the only one-time, individualized T cell therapy to receive FDA approval for a solid tumor cancer."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic centers, including the National Cancer Institute (“NCI”)."
Source: SEC EDGAR · Retrieved Nov 21, 2026

Frequently Asked Questions About Iovance Biotherapeutics (Mfg)

How many clinical programs is Iovance Biotherapeutics (Mfg) linked to?
Iovance Biotherapeutics (Mfg) is associated with 31 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Iovance Biotherapeutics (Mfg)'s CDMO Signal Score?
Iovance Biotherapeutics (Mfg) has a Signal Score of 66/100, based on quality, operations, financial stability, and capacity data.
Evaluating Iovance Biotherapeutics (Mfg) for a manufacturing program?
Use the free AI matchmaker to compare Iovance Biotherapeutics (Mfg) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Cell Therapy CDMOs →

Similar CDMOs

Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Signal Score: 73.6
mRNA, Gene Therapy, Cell Therapy, Lentiviral
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy

Compare Iovance Biotherapeutics (Mfg) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Iovance Biotherapeutics (Mfg)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.